BioSpace News Archive

Agenus Inc. today announced that Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery at Agenus, will participate in a fireside chat hosted by B. Riley on Monday, November 15, 2021 at 12:00 PM EST.

Achilles Therapeutics plc today announced its financial results for the third quarter ended September 30, 2021, and recent business highlights.

Jounce Therapeutics, Inc. today announced that company management will participate at the following upcoming investor conferences in November: 5th Annual Cowen IO Next Summit : Fireside chat on Monday, November 15, 2021 at 10:45 a.m. ET. 33rd Annual Piper Sandler Healthcare Conference

Oryzon Genomics, S.A. announced today that it will present new clinical data and present company updates at several renowned international conferences in November and December.

Rain Therapeutics Inc. today announced its plan to commence a Phase 2 linical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double minute 2 (MDM2) inhibitor, as a monotherapy for the treatment of patients with Merkel cell carcinoma (MCC) refractory to immune checkpoint inhibition (ICI) in mid-2022.

Impel NeuroPharma, Inc. today announced that Adrian Adams, Chairman and CEO, will participate in a fireside chat at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on Tuesday, November 16, 2021 at 1:40 p.m. ET.

Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual NeuroCritical Care Society (NCS) 19th Annual Meeting.

OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001, NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients

Quanta Dialysis Technologies Ltd, a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced John E. Milad, Chief Executive Officer, will be participating in three upcoming investor conferences.

Oncorus, Inc. today announced details of its upcoming presentation of initial data from the ongoing Phase 1 dose escalation and expansion clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually.